

Table 56. Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 2014¹

Reporting area	Total cases with therapy extended ^{2,3}	Reasons therapy was extended											
		Rifampin resistant		Adverse event		Nonadherence		Treatment failure		Clinically indicated		Other	
		No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
United States	825	70	(8.5)	153	(18.5)	86	(10.4)	11	(1.3)	341	(41.3)	291	(35.3)
Alabama	8	1	(12.5)	0	(0)	0	(0)	1	(12.5)	4	(50.0)	2	(25.0)
Alaska	4	1	(25.0)	0	(0)	2	(50.0)	1	(25.0)	1	(25.0)	2	(50.0)
Arizona	26	4	(15.4)	2	(7.7)	5	(19.2)	0	(0)	16	(61.5)	3	(11.5)
Arkansas	13	0	(0)	2	(15.4)	4	(30.8)	2	(15.4)	3	(23.1)	2	(15.4)
California	233	16	(6.9)	51	(21.9)	21	(9.0)	0	(0)	112	(48.1)	73	(31.3)
Colorado	4	1	(25.0)	0	(0)	1	(25.0)	0	(0)	2	(50.0)	0	(0)
Connecticut	5	0	(0)	1	(20.0)	0	(0)	0	(0)	3	(60.0)	5	(100.0)
Delaware	2	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	2	(100.0)
District of Columbia	3	0	(0)	1	(33.3)	0	(0)	0	(0)	2	(66.7)	0	(0)
Florida	40	8	(20.0)	4	(10.0)	4	(10.0)	0	(0)	24	(60.0)	2	(5.0)
Georgia	26	1	(3.8)	5	(19.2)	1	(3.8)	0	(0)	10	(38.5)	13	(50.0)
Hawaii	2	1	(50.0)	0	(0)	0	(0)	0	(0)	0	(0)	2	(100.0)
Idaho	1	1	(100.0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)
Illinois	30	1	(3.3)	4	(13.3)	3	(10.0)	0	(0)	14	(46.7)	12	(40.0)
Indiana	11	2	(18.2)	0	(0)	1	(9.1)	0	(0)	7	(63.6)	2	(18.2)
Iowa	3	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	3	(100.0)
Kansas	3	1	(33.3)	1	(33.3)	0	(0)	0	(0)	1	(33.3)	1	(33.3)
Kentucky	5	2	(40.0)	2	(40.0)	1	(20.0)	0	(0)	3	(60.0)	1	(20.0)
Louisiana	17	0	(0)	4	(23.5)	1	(5.9)	2	(11.8)	1	(5.9)	11	(64.7)
Maine	1	0	(0)	1	(100.0)	0	(0)	0	(0)	0	(0)	1	(100.0)
Maryland	21	1	(4.8)	5	(23.8)	5	(23.8)	0	(0)	4	(19.0)	9	(42.9)
Massachusetts	30	2	(6.7)	3	(10.0)	0	(0)	0	(0)	10	(33.3)	15	(50.0)
Michigan	2	0	(0)	1	(50.0)	0	(0)	0	(0)	1	(50.0)	1	(50.0)
Minnesota	11	1	(9.1)	6	(54.5)	0	(0)	0	(0)	8	(72.7)	0	(0)
Mississippi	7	0	(0)	0	(0)	0	(0)	1	(14.3)	0	(0)	6	(85.7)
Missouri	3	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	3	(100.0)
Montana	0	0	...	0	...	0	...	0	...	0	...	0	...
Nebraska	1	0	(0)	1	(100.0)	1	(100.0)	0	(0)	0	(0)	0	(0)
Nevada	4	0	(0)	4	(100.0)	0	(0)	0	(0)	0	(0)	0	(0)
New Hampshire	0	0	...	0	...	0	...	0	...	0	...	0	...
New Jersey	28	4	(14.3)	7	(25.0)	2	(7.1)	0	(0)	10	(35.7)	13	(46.4)
New Mexico	2	0	(0)	0	(0)	0	(0)	0	(0)	1	(50.0)	1	(50.0)

Table 56. (Con't) Reason Therapy Was Extended Beyond 12 Months: Reporting Areas, 2014¹

Reporting area	Total cases with therapy extended ^{2,3}	Reasons therapy was extended											
		Rifampin resistant		Adverse event		Nonadherence		Treatment failure		Clinically indicated		Other	
		No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)	No.	(%)
New York State ⁴	14	0	(0)	2	(14.3)	1	(7.1)	0	(0)	0	(0)	11	(78.6)
New York City	28	3	(10.7)	7	(25.0)	5	(17.9)	2	(7.1)	3	(10.7)	8	(28.6)
North Carolina	9	1	(11.1)	3	(33.3)	0	(0)	0	(0)	4	(44.4)	4	(44.4)
North Dakota	4	1	(25.0)	0	(0)	0	(0)	0	(0)	3	(75.0)	1	(25.0)
Ohio	14	1	(7.1)	5	(35.7)	3	(21.4)	0	(0)	5	(35.7)	0	(0)
Oklahoma	4	0	(0)	1	(25.0)	0	(0)	0	(0)	2	(50.0)	1	(25.0)
Oregon	3	1	(33.3)	2	(66.7)	0	(0)	0	(0)	0	(0)	0	(0)
Pennsylvania	33	2	(6.1)	21	(63.6)	4	(12.1)	2	(6.1)	18	(54.5)	9	(27.3)
Rhode Island	2	2	(100.0)	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)
South Carolina	2	0	(0)	0	(0)	0	(0)	0	(0)	1	(50.0)	1	(50.0)
South Dakota	1	0	(0)	1	(100.0)	0	(0)	0	(0)	0	(0)	0	(0)
Tennessee	8	1	(12.5)	1	(12.5)	2	(25.0)	0	(0)	3	(37.5)	1	(12.5)
Texas	122	5	(4.1)	0	(0)	13	(10.7)	0	(0)	54	(44.3)	55	(45.1)
Utah	1	0	(0)	0	(0)	0	(0)	0	(0)	1	(100.0)	0	(0)
Vermont	0	0	...	0	...	0	...	0	...	0	...	0	...
Virginia	15	3	(20.0)	3	(20.0)	3	(20.0)	0	(0)	5	(33.3)	5	(33.3)
Washington	12	1	(8.3)	0	(0)	3	(25.0)	0	(0)	1	(8.3)	7	(58.3)
West Virginia	1	0	(0)	0	(0)	0	(0)	0	(0)	1	(100.0)	0	(0)
Wisconsin	6	1	(16.7)	2	(33.3)	0	(0)	0	(0)	3	(50.0)	3	(50.0)
Wyoming	0	0	...	0	...	0	...	0	...	0	...	0	...
American Samoa ⁵	0	0	...	0	...	0	...	0	...	0	...	0	...
Fed. States of Micronesia ⁵	1	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	1	(100.0)
Guam ⁵	1	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	1	(100.0)
Marshall Islands ⁵	3	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	3	(100.0)
N. Mariana Islands ⁵	0	0	...	0	...	0	...	0	...	0	...	0	...
Puerto Rico ⁵	2	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	2	(100.0)
Republic of Palau ⁵	1	0	(0)	0	(0)	0	(0)	0	(0)	0	(0)	1	(100.0)
U.S. Virgin Islands ⁵	0	0	...	0	...	0	...	0	...	0	...	0	...

¹Most recent year for which data are available.

²Among patients who were alive at diagnosis, started on treatment and had a duration of treatment >365 days.

³Patient may have more than one reason therapy was extended beyond 12 months (total reasons therapy extended may be greater than total patients with therapy extended).

⁴Excludes New York City.

⁵Not included in U.S. totals.

Note: Ellipses (...) indicate that the percentage cannot be calculated, and the denominator is 0.